Filtering

Page: () 1 ... 176 177 178 179 180 181 182
P493: Prevalence and risk factors for postoperative septic complications in Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

M. Guasch1, 2, A. Clos1, M. Manyosa3, T. Lobatón3, J. R. Gómez2, M. Piñol4, E. Cabré3, J. Troya4, E. Domènech*3

1Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 2Hospital San Jorge, Digestive Surgery, Huesca, Spain, 3Hospital Germans Trias i Pujol. CIBEREHD, Gastroenterology, Badalona, Spain, 4Hospital Universitari Germans Trias i Pujol, Digestive Surgery, Badalona, Spain

P494: Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

G. Maurizi, M. Giannotta*, V. Almerigogna, S. Biagini, A. Cozzi, G. Macrì, M. Milla

AOU Careggi, Regional Referral Centre of Inflammatory Bowel Disease - Clinical Gastroenterology Division, Florence, Italy

P495: Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naïve to anti-TNF therapy: a tertiary centre experienceECCO '16 Amsterdam
Year: 2016
Authors:

M. Bortlik*1, 2, M. Kolar1, D. Duricova1, 3, K. Malickova4, V. Hruba1, N. Machkova1, K. Mitrova1, M. Lukas1, M. Lukas1, 4

1Iscare, IBD Clinical and Research Centre, Prague, Czech Republic, 2First Medical Faculty and Central Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, 3First Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, 4First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic

P496: Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn’s disease: a pooled analysisECCO '16 Amsterdam
Year: 2016
Authors:

E. J. Louis*1, R. Löfberg2, W. Reinisch3, D. Schwartz4, J.-F. Maa5, S. Berg5, B. Huang5, A. W. Wang5, A. M. Robinson5, B. Pappalardo5

1University of Liège and CHU, Liège, Belgium, 2Karolinska Institutet and IBD Unit, Sophiahemmet, Stockholm, Sweden, 3Medical University of Vienna, Vienna, Austria, 4Vanderbilt University Medical Centre, Nashville, United States, 5AbbVie Inc., North Chicago, Illinois, United States

P497: Clinical features and outcomes of tuberculosis in inflammatory bowel disease patients treated with anti-TNF therapy as compared with the general populationECCO '16 Amsterdam
Year: 2016
Authors:

J. Kim*1, J. P. Im1, J.-J. Yim2, C. K. Lee3, D. I. Park4, C. S. Eun5, S.-A. Jung6, J.E. Shin7, K.-M. Lee8, J. H. Cheon9

1Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 2Seoul National University College of Medicine, Department of Internal Medicine and Lung Institute, Seoul, South Korea, 3Kyung Hee University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 4Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 5Hanyang University, Department of Internal Medicine, Guri, South Korea, 6Ewha Woman’s University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 7Dankook University College of Medicine, Department of Internal Medicine, Cheonan, South Korea, 8The Catholic University of Korea College of Medicine, Department of Internal Medicine, Seoul, South Korea, 9Yonsei University College of Medicine, Department of Internal Medicine, Seoul, South Korea

P498: Rephrasing the question: a novel simple tool for a more accurate evaluation of inflammatory bowel disease patients’ adherence to therapyECCO '16 Amsterdam
Year: 2016
Authors:

T. Engel*1, G. Ben-Haim2, N. Levhar1, R. Eliakim1, S. Ben-Horin1

1Sheba Medical Centre Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Gastroenterology, Ramat Gan, Israel, 2Sheba Medical Centre Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Internal Medicine C, Ramat Gan, Israel

P499: Long-term outcomes of infliximab and predictors of response in 213 patients with ulcerative colitis: a hospital-based cohort study from KoreaECCO '16 Amsterdam
Year: 2016
Authors:

H. Seo*1, S. H. Park1, K. Chang1, G.-U. Kim1, E. M. Song1, M. Seo1, H.-S. Lee2, S.W. Hwang1, D.-H. Yang1, B. D. Ye1, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang1

1Asan Medical Centre, University of Ulsan College of Medicine, Department of Gastroenterology, Seoul, South Korea, 2Asan Medical Centre, University of Ulsan College of Medicine, Health Screening and Promotion Centre, Seoul, South Korea

P500: Capsule endoscopy reveals small intestinal mucosal Crohn’s disease healing after treatment with adalimumab: preliminary results of the SIMCHA studyECCO '16 Amsterdam
Year: 2016
Authors:

E. Seidman*1, U. Kopylov2, C.-Y. Chao1, M. Girardin3, M. Starr4

1Research Institute of the McGill University Hospital, Gastroenterology, Montreal, Canada, 2Sheba Medical Centre, Gastroenterology, Tel Hashomer, Tel Aviv, Israel, 3University Hospital of Geneva, Department of Gastroenterology and Hepatology, Geneva, Switzerland, 4Research Institute of the McGill University Health Centre, Rheumatology, Montreal, Canada

P501: Abdominal obesity in Paediatric Crohn’s disease is associated with adipokine dysregulationECCO '16 Amsterdam
Year: 2016
Authors:

D. Thangarajah*1, K. E. Chapell1, S. Mandalia1, G. Frost2, J. M. Fell3

1Imperial College, Section of Academic Neonatal Medicine, London, United Kingdom, 2Imperial College, Nutrition and Dietetic Research Group, Faculty of Medicine, London, United Kingdom, 3Chelsea and Westminster Hospital NHS Foundation Trust, Department of Paediatric Gastroenterology, London, United Kingdom

P502: Persistence of remission amongst patients with inflammatory bowel disease after adalimumab therapy is stopped: economic and clinical implicationsECCO '16 Amsterdam
Year: 2016
Authors:

x. Cortés*1, J. R. MOLÉS2, S. Fernández3, J. Clofent3, M. Moreno4, J. Rodriguez3, J. Primo3

1Hospital de Sagunto, Valencia, Spain, 2HOSPITAL DE SAGUNTO, VALENCIA, Spain, 3HOSPITAL DE SAGUNTO, Valencia, Spain, 4Hospital de sagunto, Valencia, Spain

P503: Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational studyECCO '16 Amsterdam
Year: 2016
Authors:

T. Yamamoto*, T. Shimoyama, S. Umegae, K. Matsumoto

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P504: Stability observations in tacrolimus suppositoriesECCO '16 Amsterdam
Year: 2016
Authors:

M. Lie*1, E. Jansen2, P. Hoeben2, R. Zaal3, D. Hodes2, M. Rosman2, W. Loos2, J. van der Woude1

1Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands, 2TioFarma BV, Oud-Beijerland, Netherlands, 3Erasmus Medical Centre, Hospital Pharmacy, Rotterdam, Netherlands

P505: The effect of using a question prompt list in outpatient clinic consultations in a Dutch inflammatory bowel disease populationECCO '16 Amsterdam
Year: 2016
Authors:

N. Peek-Kuijt*1, M. de Jong1, N. Srivastava2, R. Veenendaal1, P. Maljaars1, L. van Bodegom-Vos3, A. Linn4, A. van der Meulen-de Jong1

1Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 2Medical Centre Haaglanden, Department of Gastroenterology and Hepatology, The Hague, Netherlands, 3Leiden University Medical Centre, Department of Medical Decision Making, Leiden, Netherlands, 4University of Amsterdam, Amsterdam School of Communication Research (ASCoR), Amsterdam, Netherlands

P506: Serum infliximab and antibodies to infliximab levels in Crohn’s disease and ulcerative colitis patients on long-term maintenance therapyECCO '16 Amsterdam
Year: 2016
Authors:

M. Waterman*1, H. Bar Yoseph1, B. Ungar2, S. Ben - Horin2, Y. Chowers1

1Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel, 2Sheba Medical Centre, Department of Gastroenterology, Ramat Gan, Israel

P507: Clinical role, optimal timing and frequency of measurement of serum infliximab levels and anti-infliximab antibody titres in patients with inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

R. Bor*1, K. Farkas1, A. Bálint1, A. Milassin1, M. Rutka1, M. Matuz2, F. Nagy1, A. Fábián1, Z. Szepes1, T. Molnar1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Faculty of Pharmacy, Szeged, Hungary

P508: Pregnancy outcomes in patients with inflammatory bowel disease experiencing flare ups during foetal developmentECCO '16 Amsterdam
Year: 2016
Authors:

Y. Yokoyama*1, H. Tanaka2, T. Miyazaki1, T. Sato1, M. Kawai1, Y. Kita1, K. Kamikozuru1, M. Iimuro1, N. Hida1, S. Nakamura1

1Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine, Nishinomiya, Japan, 2Hyogo College of Medicine, Department of Obstetrics and Gynaecology, Nishinomiya, Japan

P509: What is the effect of inflammatory bowel disease on sedation rates at colonoscopy?ECCO '16 Amsterdam
Year: 2016
Authors:

M. Walshe*, C. Moran, G. Horgan, G. Cullen, H. Mulcahy, G. Doherty

St Vincent’s University Hospital, Department of Gastroenterology and Centre for Colorectal Disease, Dublin, Ireland

P510: Skin anergy and latent tuberculosis in inflammatory bowel disease patientsECCO '16 Amsterdam
Year: 2016
Authors:

C. Herrera de Guise*, V. Robles, N. Borruel, E. Navarro, F. Casellas

Unitat d’Atenció Crohn-Colitis. Hospital Universitari Vall d’Hebron, Digestive Diseases Research, Barcelona, Spain

P511: Utilisation and efficacy of oral iron therapy in patients with iron deficiency anaemia in a nationwide cohort of ulcerative colitis patientsECCO '16 Amsterdam
Year: 2016
Authors:

D. Patel*1, N. Khan2

1Mercy Catholic Medical Centre, Internal Medicine, Philadelphia, Pennsylvania, United States, 2University of Pennsylvania, Internal Medicine, Philadelphia, Pennsylvania, United States

Page: () 1 ... 176 177 178 179 180 181 182